Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival
Immune-related adverse events were associated with improved survival outcomes.
Diagnosis & Disease Information
Immunotherapy, Chemotherapy Combination Improves Survival in Advanced Esophageal Cancer
Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.
Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Preexisting Autoimmune Disease Increases Incidence of irAEs With PD-1 Immunotherapy for Advanced Cancer
Study findings demonstrate the rates of immune-related adverse events and flares of the underlying disorders in this patient population.
Chronic Immune-Mediated Diarrhea and Colitis Associated With Prolonged Survival in Patients Treated With ICIs
The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.
Current State of Combination Therapy for Checkpoint Inhibitors
Despite the clinical success of combination therapy with immune checkpoint inhibitors many research questions still remain.
Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Phase 1 RCC Vaccine Is Safe, But Lacks Clinical Response
RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...